NEW YORK (GenomeWeb News) — Cellectis has sub-licensed to GlaxoSmithKline patents for a process used to replace, remove, or insert genes in a genome by homologous recombination, Cellectis said Friday.
 
The company, which licensed the technology from the Pasteur Institute, said GlaxoSmithKline will use it in its drug research for in vitro and in vivo “modifications and manipulations of genetic material.”
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.